However, despite the numerous preclinical and clinical trials investigating anti-EGFR inhibitors in breast cancer, only two of them, Lapatinib and Neratinib, have been approved by the Federal Drug Administration (FDA). This evidence concerns the gene EGFR and breast carcinoma.